GFAP and dementia: In this cohort study, compared with non–APOE4 carriers, neurodegenerative serum biomarkers of t-tau, NfL, and GFAP were associated with lower baseline cognitive function levels and a faster cognitive decline rate among APOE4 carriers without dementia.